Cargando…

Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?

Hepcidin is upregulated by inflammation and iron. Inherited (HFE genotype) and treatment-related factors (blood units (BU), Iron overload) affecting hepcidin (measured by C-ELISA) were studied in 42 consecutive patients with AML prior to and after allogeneic hematopoietic cell transplantation (HCT)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisfeld, Ann-Kathrin, Westerman, Mark, Krahl, Rainer, Leiblein, Sabine, Liebert, Uwe Gerd, Hehme, Marianne, Teupser, Daniel, Niederwieser, Dietger, Al-Ali, Haifa Kathrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112503/ https://www.ncbi.nlm.nih.gov/pubmed/21687645 http://dx.doi.org/10.1155/2011/491058

Ejemplares similares

Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia
por: Cross, Michael, et al.
Publicado: (2013)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials
por: Heinicke, Thomas, et al.
Publicado: (2021)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Hepcidin antagonists for potential treatments of disorders with hepcidin excess
por: Poli, Maura, et al.
Publicado: (2014)

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
por: Backhaus, Donata, et al.
Publicado: (2022)

The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world
por: Okamoto, Shinichiro, et al.
Publicado: (2022)

Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant
por: Pirotte, Michelle, et al.
Publicado: (2021)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
por: Hell, Saskia, et al.
Publicado: (2022)

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
por: Jentzsch, Madlen, et al.
Publicado: (2017)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells
por: Werner, Melanie, et al.
Publicado: (2015)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge
por: Niederwieser, Dietger
Publicado: (2021)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation
por: Sakamoto, Soichiro, et al.
Publicado: (2016)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Comparison of three malnutrition screening tools prior to allogeneic hematopoietic stem-cell transplantation
por: Khosroshahi, Reza Amiri, et al.
Publicado: (2023)

EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression - a case report
por: Krenauer, Alexander, et al.
Publicado: (2010)

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome
por: Franke, Georg-Nikolaus, et al.
Publicado: (2021)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2018)

A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults
por: Apsel Winger, Beth, et al.
Publicado: (2021)

Unbiased decision-making for acute myeloid leukemia still needed
por: Eisfeld, Ann-Kathrin
Publicado: (2022)

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation
por: Fürst, Daniel, et al.
Publicado: (2017)

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies
por: Paiano, Sandra, et al.
Publicado: (2015)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial
por: Panwar, Bhupesh, et al.
Publicado: (2018)

Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
por: Lee, Jae Wook, et al.
Publicado: (2021)

Molecular Mechanisms Regulating Hepcidin Revealed by Hepcidin Disorders
por: Camaschella, Clara, et al.
Publicado: (2011)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Hepcidin in Children and Adults with Acute Leukemia or Undergoing Hematopoietic Cell Transplantation: A Systematic Review
por: Słomka, Artur, et al.
Publicado: (2022)

Hepcidin Therapeutics
por: Katsarou, Angeliki, et al.
Publicado: (2018)

Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: El‐Serafi, Ibrahim, et al.
Publicado: (2019)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vnkhsdjnfim4hladmijadebrdl